Positive data from pivotal phase III study could improve standard of care for Hodgkin lymphoma patients
Monday, December 8, 2014 - 16:01
in Health & Medicine
In a late-stage clinical trial, Hodgkin lymphoma patients who received brentuximab vedotin post-transplant lived longer without disease progression than patients who received only supportive care, researchers report.